Replies to post #218476 on Biotech Values

[DewDiligence]

GILD’s Selonsertib—(ASK1 inhibitor)—fails phase-3 in NASH patients with cirrhosis:

https://www.businesswire.com/news/home/20190211005738/en/Gilead-Announces-Topline-Data-Phase-3-STELLAR-4

In the study of 877 enrolled patients who received study drug, 14.4 percent of patients treated with selonsertib 18 mg (p=0.56 vs. placebo) and 12.5 percent of patients treated with selonsertib 6 mg (p=1.00 [vs placebp]) achieved a >=1-stage improvement in fibrosis…without worsening of NASH after 48 weeks of treatment, compared with 12.8 percent of patients who received placebo.

[DewDiligence]

GILD’s (rather modest) EASL PR:

https://www.gilead.com/news-and-press/press-room/press-releases/2019/4/gilead-presents-new-data-in-nonalcoholic-steatohepatitis-nash-at-the-international-liver-congress-2019